Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_assertion type Assertion NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_head.
- NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_assertion description "[Ibrutinib (previously known as PCI-32765) has recently shown encouraging clinical activity in chronic lymphocytic leukaemia (CLL) effecting cell death through inhibition of Bruton's tyrosine kinase (BTK).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_provenance.
- NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_assertion evidence source_evidence_literature NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_provenance.
- NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_assertion SIO_000772 22975686 NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_provenance.
- NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_assertion wasDerivedFrom befree-20140225 NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_provenance.
- NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_assertion wasGeneratedBy ECO_0000203 NP673045.RAIIrByEeOAobDE-Ag3QADKfJ9WjDGpeBskF5yoOoKPvk130_provenance.